A Brief Fundamentals on Osteoporosis

This chapter gives immense information about the various questionnaires assess the quality of life of the osteoporosis patents such as SF-36, ADL Hannover ADL scope, QUALIOST- QOL Questionnaire in Osteoporosis and QUALIFO 41- QOL Questionnaire of European Foundation of Osteoporosis.

Primary osteoporosis is due to estrogen loss and aging while secondary osteoporosis is due to the systemic illness or medications such as glucocorticoids or phenytoin. Osteoporosis is the progressive loss of bone density and bone tissue thickness. In western society, osteoporosis is a serious and expanding public health concern for older women and men. The primary storehouse of calcium and phosphate, bone undergoes continual remodelling as a result of stress; numerous factors have an impact on bone resorption. Understanding the physiology, pathophysiology and treatment of osteoporosis will direct the patients about precautions to be taken, to select the correct treatment regimen and to improve the quality of life of the patients. The beneficial effects of treatments can be assessed by the outcome study using quality of life assessment tools. Hormone replacement therapy (HRT) is a second-line option in most, although it has a place in the management of perimenopausal women with menopausal symptoms who are at risk from fracture and in other postmenopausal women who express a preference for HRT over other options, after being fully informed about known risks and benefits.